[go: up one dir, main page]

PE20230382A1 - Nueva composicion farmaceutica para administracion de farmacos - Google Patents

Nueva composicion farmaceutica para administracion de farmacos

Info

Publication number
PE20230382A1
PE20230382A1 PE2022002543A PE2022002543A PE20230382A1 PE 20230382 A1 PE20230382 A1 PE 20230382A1 PE 2022002543 A PE2022002543 A PE 2022002543A PE 2022002543 A PE2022002543 A PE 2022002543A PE 20230382 A1 PE20230382 A1 PE 20230382A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
drug administration
new pharmaceutical
pharmaceutically acceptable
composition
Prior art date
Application number
PE2022002543A
Other languages
English (en)
Inventor
Jonas Savmarker
Robert Ronn
Andreas Fischer
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2007306.0A external-priority patent/GB202007306D0/en
Priority claimed from GBGB2009905.7A external-priority patent/GB202009905D0/en
Priority claimed from GBGB2018901.5A external-priority patent/GB202018901D0/en
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of PE20230382A1 publication Critical patent/PE20230382A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmaceuticamente aceptable, tal composicion esta en la forma de un polvo secado por aspersion que comprende una mezcla de: (a) una cantidad de dosis farmacologicamente efectiva de al menos un compuesto farmacologicamente activo; y (b) un material portador farmaceuticamente aceptable, tal material portador comprende una combinacion de un disacarido y un material polimerico.
PE2022002543A 2020-05-18 2021-05-18 Nueva composicion farmaceutica para administracion de farmacos PE20230382A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2007306.0A GB202007306D0 (en) 2020-05-18 2020-05-18 New pharmaceutical composition
GBGB2009905.7A GB202009905D0 (en) 2020-06-29 2020-06-29 New pharmaceutical composition
GBGB2018901.5A GB202018901D0 (en) 2020-12-01 2020-12-01 New pharmaceutical composition
PCT/GB2021/051191 WO2021234366A1 (en) 2020-05-18 2021-05-18 New pharmaceutical composition for drug delivery

Publications (1)

Publication Number Publication Date
PE20230382A1 true PE20230382A1 (es) 2023-03-06

Family

ID=76138084

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002543A PE20230382A1 (es) 2020-05-18 2021-05-18 Nueva composicion farmaceutica para administracion de farmacos

Country Status (25)

Country Link
US (2) US11737980B2 (es)
EP (2) EP4154866A1 (es)
JP (1) JP2023526098A (es)
KR (1) KR20230012502A (es)
CN (1) CN115666513B (es)
AU (1) AU2021276611A1 (es)
BR (1) BR112022023307A2 (es)
CA (1) CA3178769A1 (es)
CL (1) CL2022002979A1 (es)
CO (1) CO2022015183A2 (es)
DK (1) DK3962455T3 (es)
ES (1) ES2929818T3 (es)
HR (1) HRP20221361T1 (es)
HU (1) HUE060573T2 (es)
IL (1) IL297658A (es)
LT (1) LT3962455T (es)
MD (1) MD3962455T2 (es)
MX (1) MX2022014216A (es)
PE (1) PE20230382A1 (es)
PL (1) PL3962455T3 (es)
PT (1) PT3962455T (es)
RS (1) RS63725B1 (es)
SI (1) SI3962455T1 (es)
SM (1) SMT202200411T1 (es)
WO (1) WO2021234366A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
KR20230012502A (ko) 2020-05-18 2023-01-26 오렉쏘 에이비 약물 전달을 위한 신규한 약학 조성물
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
WO2023094818A1 (en) * 2021-11-25 2023-06-01 Orexo Ab Pharmaceutical composition comprising biopharmaceutical drug compounds
KR20240103005A (ko) * 2021-11-25 2024-07-03 오렉쏘 에이비 아드레날린을 포함하는 약학적 조성물
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
US20250205153A1 (en) 2022-03-31 2025-06-26 Hovione Scientia Limited Inhalation composite and carrier based formulation combination
EP4514376A1 (en) * 2022-04-29 2025-03-05 Pentide Therapeutics Limited Pharmaceutical compositions of semaglutide and the methods of use thereof
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
CN119768160A (zh) * 2022-08-11 2025-04-04 德莫图科迪斯私人有限公司 可吸入肾上腺素制剂
GB202301322D0 (en) * 2023-01-30 2023-03-15 Therakind Ltd Antiemetic pharmaceutical compositions for nasal delivery
WO2024226493A2 (en) * 2023-04-24 2024-10-31 Cyrano Therapeutics, Inc. Treatment of memory loss with phosphodiesterase inhibitors
WO2024246554A1 (en) * 2023-05-31 2024-12-05 Orexo Ab Spray-dried compositions comprising adrenergic receptor modulators
GB202308123D0 (en) * 2023-05-31 2023-07-12 Orexo Ab New copmosition
WO2024258475A1 (en) * 2023-06-14 2024-12-19 Genus Lifesciences Inc. Pharmaceutical oral solid dosage forms including phenobarbital and methods of making and using the same

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759520A (fr) 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
SE8904296D0 (sv) 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
EP0657176B1 (en) 1993-12-06 2000-09-20 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
JP4462761B2 (ja) 1998-03-10 2010-05-12 バルワー エス．アー． 格納容器に格納された液体製品を投与する装置、及び格納容器の充填方法
SK262001A3 (en) * 1998-07-08 2001-09-11 Kirin Amgen Inc Powdery preparation for mucosal administration containing polymeric medicine
JP2000178184A (ja) 1998-12-17 2000-06-27 Lion Corp 粒状組成物、錠剤及び粒状組成物の製造方法
GB9908921D0 (en) 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
GB0003782D0 (en) 2000-02-17 2000-04-05 Dumex Ltd As Process
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
KR20010107754A (ko) 2000-05-26 2001-12-07 민경윤 경구투여용 속용정의 제조 방법
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
IN192750B (es) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US6443152B1 (en) 2001-01-12 2002-09-03 Becton Dickinson And Company Medicament respiratory delivery device
LU90825B1 (en) 2001-09-06 2003-03-07 Iee Sarl Method for the determination of one or more parameters of a seat passenger
ITMI20012174A1 (it) 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0201367D0 (en) 2002-01-22 2002-03-13 Ml Lab Plc Composition
AU2006207868A1 (en) 2002-03-20 2006-09-28 Alkermes, Inc. Method and apparatus for producing dry particles
EP3308772B8 (en) 2002-06-28 2021-03-17 Civitas Therapeutics, Inc. Inhalable epinephrine
AU2003296954A1 (en) 2002-12-13 2004-07-09 The Regents Of The University Of California Analgesic combination comprising nalbuphine
WO2004075877A1 (en) 2003-02-24 2004-09-10 Pharmaceutical Productions, Inc. Transmucosal drug delivery system
US20060115529A1 (en) 2003-05-07 2006-06-01 Seonghoon Jeong Fast-melting tablets having taste-masking and sustained release properties
CA2524806C (en) 2003-05-07 2011-07-12 Akina, Inc. Highly plastic granules for making fast melting tablets
AU2004249166B2 (en) 2003-06-13 2008-10-09 Alkermes, Inc. Low dose pharmaceutical powders for inhalation
CN100471497C (zh) 2003-06-25 2009-03-25 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻粉剂
US20050042178A1 (en) 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
EP1671667A4 (en) 2003-10-09 2013-05-01 Shin Nippon Biomedical Lab Ltd NASAL PULVERULENT DRUG DELIVERY DEVICE
WO2005044186A2 (en) 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
CN1640402A (zh) 2004-01-02 2005-07-20 广东奇方药业有限公司 一种稳定的纳洛酮粉针剂
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
CN1615867A (zh) 2004-10-22 2005-05-18 北京阳光润禾科技有限公司 注射用盐酸纳洛酮冻干粉针制剂
CN1781479B (zh) 2004-12-02 2010-06-30 和记黄埔医药企业有限公司 一种马蔺子素分散体系及其制备方法
US20080317863A1 (en) 2005-02-10 2008-12-25 Christer Nystrom Pharmaceutical Compositions Useful in the Transmucosal Administration of Drugs
KR101233235B1 (ko) 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
WO2014007972A2 (en) * 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine
US20070202163A1 (en) 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
CN1939358A (zh) 2005-09-30 2007-04-04 江西本草天工科技有限责任公司 肿节风分散片
CN1813739A (zh) 2005-11-25 2006-08-09 王颖 一种注射用盐酸纳美芬冻干粉针制剂
EP1976486A1 (en) 2006-01-27 2008-10-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
WO2007096906A2 (en) 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
US20100226979A1 (en) 2006-03-21 2010-09-09 Jubilant Organosys Limited Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate
AU2007232098A1 (en) 2006-03-31 2007-10-11 Rubicon Research Private Limited Directly compressible composite for orally disintegrating tablets
ATE516796T1 (de) 2006-09-15 2011-08-15 Echo Pharmaceuticals Bv Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür
US20080269347A1 (en) 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
WO2008127746A1 (en) 2007-01-10 2008-10-23 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
WO2009113522A1 (ja) 2008-03-11 2009-09-17 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
US20090246256A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
US20090264530A1 (en) 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
EP2432502B1 (en) * 2009-05-20 2018-01-03 Aeras Stable, spray dried, immunogenic, viral compositions
TWI792140B (zh) * 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
DK2480197T3 (en) 2009-09-25 2016-01-25 Reddys Lab Ltd Dr Compositions containing triptanforbindelser
US20120064157A1 (en) 2010-08-27 2012-03-15 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
CA2809666C (en) * 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
KR20140011300A (ko) 2010-10-01 2014-01-28 시플라 리미티드 데페라시록스를 포함하는 약학 조성물
EP2646003B1 (en) 2010-12-02 2020-06-03 Adare Pharmaceuticals, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
ES2832973T3 (es) 2011-02-18 2021-06-11 Biolingus Ip Llc Procedimiento para preparar productos que comprenden principios activos estabilizados y composiciones que comprenden los mismos
CA2835940C (en) 2011-05-13 2020-08-04 Euro-Celtique S.A. Intranasal pharmaceutical dosage forms comprising naloxone
MX341663B (es) 2012-05-11 2016-08-30 Activus Pharma Co Ltd Nanopolvo de compuesto organico, metodo para producirlo y su suspension.
US9789071B2 (en) * 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
WO2014004400A2 (en) 2012-06-28 2014-01-03 The Governt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Nasal dry powder delivery system for vaccines and other treatment agents
FR3007992B1 (fr) 2013-07-05 2018-01-26 Aptar France Sas Dispositif de distribution de produit fluide ou pulverulent.
CA2923270A1 (en) 2013-09-03 2015-03-12 Shin Nippon Biomedical Laboratories Ltd. (Snbl) Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
WO2015095389A1 (en) 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
ES2952025T3 (es) * 2014-04-04 2023-10-26 Ai Therapeutics Inc Una formulación de rapamicina inhalable para tratar condiciones relacionadas con la edad
US20190008759A1 (en) 2014-07-03 2019-01-10 Darren Rubin Safer and more effective methods of transmucosal delivery for raising blood pressure and stimulating the body
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3174534A1 (en) 2014-08-01 2017-06-07 KRKA, d.d., Novo mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
WO2016044813A1 (en) 2014-09-18 2016-03-24 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
CA2962531C (en) 2014-10-08 2023-05-23 Eratech S.R.L. Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
EP3220893B1 (en) 2014-11-14 2023-06-07 Asoltech Srl Composition based on coq10
EP3025705B8 (en) 2014-11-25 2018-11-28 Sanofi Ilaç Sanayi ve Ticaret Anonim Sirketi Stable ivabradine formulations
CN104547220A (zh) 2014-12-30 2015-04-29 陈宏� 一种治疗儿童视觉疲劳的中药组合物及其制剂
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
EP3673900B1 (en) 2015-02-17 2025-06-25 Amphastar Pharmaceuticals, Inc. Nasal powder formulation for treatment of hypoglycemia
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
EP3280740A4 (en) 2015-04-08 2019-03-27 Ling, Chang-Chun PHARMACEUTICAL COMPOSITIONS OF POLYANIONIC AND NONIONIC CYCLODEXTRIN BASED DENDRIMERS AND USES THEREOF
CA2984339A1 (en) 2015-05-01 2016-11-10 Civitas Therapeutics, Inc. Zolmitriptan powders for pulmonary delivery
US10039710B2 (en) 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
CA3011185A1 (en) 2016-01-20 2017-07-27 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
ITUB20161027A1 (it) * 2016-02-24 2017-08-24 Altergon Sa Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio
BR112018068855A2 (pt) 2016-03-16 2019-01-22 Omegatri As pós e comprimidos que compreendem os derivados de ácido graxos de omega-3 e os métodos de sua produção
US20170312226A1 (en) 2016-04-28 2017-11-02 Ascent Pharmaceuticals, Inc. Pharmaceutical dosage forms
SG11201810628XA (en) 2016-06-03 2018-12-28 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
US20190350881A1 (en) 2016-06-17 2019-11-21 Ys Pharmtech Stabilization of epinephrine formulations
US20190307156A1 (en) 2016-07-06 2019-10-10 Mccormick & Company, Incorporated Natural encapsulation flavor products
CA3030359A1 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
AU2017336776A1 (en) 2016-09-28 2019-03-21 Chrono Therapeutics Inc. Transdermal drug delivery device for delivering opioids
WO2018064672A1 (en) 2016-09-30 2018-04-05 Opiant Pharmaceuticals, Inc. Treatment with intranasal naloxone
US20180092839A1 (en) 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
EP3538189A4 (en) 2016-11-09 2020-04-22 Opiant Pharmaceuticals, Inc. COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF CONDITIONS MEDIATED BY AN OPIOID RECEPTOR
WO2018093666A1 (en) 2016-11-18 2018-05-24 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
WO2018148382A1 (en) 2017-02-10 2018-08-16 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi-chambered delivery system for mucosal delivery
JP2020516688A (ja) 2017-04-17 2020-06-11 ヒクマ・ファーマシューティカルズ・ユー・エス・エイ・インコーポレイテッド エピネフリンスプレー製剤
EP3668490A4 (en) 2017-08-20 2021-06-09 Formulex Pharma Innovations Ltd. Dry powder compositions for intranasal delivery
US20180193332A1 (en) 2017-10-09 2018-07-12 Adapt Pharma Operations Limited Low-temperature stable opioid antagonist solutions
US11077075B2 (en) 2018-01-10 2021-08-03 Hikma Pharmaceuticals Usa Inc. Methods of stabilizing epinephrine
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CA3102815A1 (en) 2018-06-13 2019-12-19 Hikma Pharmaceuticals Usa Inc. Epinephrine spray formulations
JP7679968B2 (ja) 2019-03-29 2025-05-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 呼吸器疾患における肺機能を改善するための気管支拡張剤としての吸入スタチン
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US11400045B2 (en) 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
KR20230012502A (ko) 2020-05-18 2023-01-26 오렉쏘 에이비 약물 전달을 위한 신규한 약학 조성물
US11617716B2 (en) 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
KR20240103005A (ko) 2021-11-25 2024-07-03 오렉쏘 에이비 아드레날린을 포함하는 약학적 조성물

Also Published As

Publication number Publication date
HUE060573T2 (hu) 2023-03-28
PT3962455T (pt) 2022-10-13
SMT202200411T1 (it) 2022-11-18
CL2022002979A1 (es) 2023-05-12
CA3178769A1 (en) 2021-11-25
WO2021234366A1 (en) 2021-11-25
US20220087938A1 (en) 2022-03-24
DK3962455T3 (en) 2022-10-24
KR20230012502A (ko) 2023-01-26
US11737980B2 (en) 2023-08-29
ES2929818T3 (es) 2022-12-02
EP4154866A1 (en) 2023-03-29
PL3962455T3 (pl) 2023-01-16
MD3962455T2 (ro) 2022-12-31
IL297658A (en) 2022-12-01
US20240024244A1 (en) 2024-01-25
MX2022014216A (es) 2022-12-07
AU2021276611A1 (en) 2022-12-15
EP3962455A1 (en) 2022-03-09
CN115666513B (zh) 2025-09-30
BR112022023307A2 (pt) 2022-12-20
US12357573B2 (en) 2025-07-15
LT3962455T (lt) 2022-10-25
RS63725B1 (sr) 2022-12-30
CN115666513A (zh) 2023-01-31
JP2023526098A (ja) 2023-06-20
CO2022015183A2 (es) 2023-02-27
EP3962455B1 (en) 2022-08-31
SI3962455T1 (sl) 2022-11-30
HRP20221361T1 (hr) 2023-01-06

Similar Documents

Publication Publication Date Title
PE20230382A1 (es) Nueva composicion farmaceutica para administracion de farmacos
UY27908A1 (es) Formulaciones y formas de dosificación para la administración controlada de topiramato
CL2022000033A1 (es) Composición farmacéutica para suministro nasal
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
GB2596884A8 (en) Pharmaceutical composition
AR088875A1 (es) Forma de dosis farmaceutica oral a prueba de manipulacion
ECSP088403A (es) Formulacion farmaceutica de absorción oral y su método de administracion
AR017694A1 (es) Una composicion para la administracion nasal de un farmaco para tratar la disfuncion erectil, el uso de dicha composicion en la fabricacion de unmedicamento, y un procedimiento para la preparacion de la composicion
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
CO5640072A2 (es) Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacion
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
AR127780A1 (es) Nueva composición farmacéutica que comprende adrenalina
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
MX2024013213A (es) Formulaciones de endoxifeno en dosis altas y metodos de uso
BRPI0512230A (pt) método para minimizar a retenção de pó sobre superfìcies
CO5700794A2 (es) Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas
ECSP003685A (es) Formulaciones orales de liberacion controlada
CR9324A (es) Preparación farmacéutica para la anticoncepción oral
MX2021004553A (es) Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda.
MX2022013103A (es) Nueva composicion farmaceutica multiparticulada de tamsulosina y solifenacina.
PE20251269A1 (es) Nuevo cocristal de enavogliflozina
AR132834A1 (es) Composiciones secadas por pulverización que comprenden moduladores del receptor adrenérgico
AR118056A2 (es) Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y uso de las mismas
AR131566A1 (es) Formulaciones farmacéuticas de sildenafilo mejoradas